Pelthos Therapeutics Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
CONSOLIDATED BALANCE SHEETS
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $131,317 | $513,443 |
| Prepaid expenses | 16,337 | 65,300 |
| Due from Chromocell Corporation | 40,400 | 40,400 |
| Deferred offering costs | 723,125 | 750,000 |
| TOTAL CURRENT ASSETS | 911,179 | 1,369,143 |
| TOTAL ASSETS | $911,179 | $1,369,143 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $2,603,605 | $1,897,127 |
| Loan payable, net of debt discount | 2,371,540 | 2,054,202 |
| Loan payable - related party, net of debt discount | 131,868 | 131,868 |
| TOTAL CURRENT LIABILITIES | 5,107,013 | 4,083,197 |
| TOTAL LIABILITIES | 5,107,013 | 4,083,197 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock Series A, $0.0001 par value, 700,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | — |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,183,562 and 6,103,813 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 621 | 613 |
| Additional paid in capital | 19,246,143 | 18,760,320 |
| Accumulated deficit | (23,442,598) | (21,474,987) |
| TOTAL STOCKHOLDERS’ DEFICIT | (4,195,834) | (2,714,054) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $911,179 | $1,369,143 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.